3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Status
Active not recruiting
3
Recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Lung Neoplasms
44
Carcinoma, Hepatocellular
42
Small Cell Lung Carcinoma
28
Breast Neoplasms
18
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
16
Biliary Tract Neoplasms
15
Liver Neoplasms
13
Neoplasms
12
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
9
Carcinoma
9
Squamous Cell Carcinoma of Head and Neck
8
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Transitional Cell
6
Melanoma
5
Gallbladder Neoplasms
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Prostatic Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Mesothelioma
4
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
durvalumab
×
1 year
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT06606847
2026-05-15
LADOGA
AstraZeneca
Phase 2
Active not recruiting
30 enrolled
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled